Rachel Abbott
Chief Executive Officer at Pan Cancer T
Profile
Rachel Abbott is currently the Chief Executive Officer at Pan Cancer T.
She has a graduate and doctorate degree from the University of Oxford.
Rachel Abbott active positions
| Companies | Position | Start |
|---|---|---|
Pan Cancer T
 Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Chief Executive Officer | 2023-05-11 |
Training of Rachel Abbott
| University of Oxford | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Pan Cancer T
Pan Cancer T BiotechnologyHealth Technology Pan Cancer T is a company based in Rotterdam, Netherlands that was founded in 2020 by Reno Debets, Dora Hammerl. The Dutch company focuses on advancing next generation TCR T cell therapies for hard-to-treat solid tumors. The company's approach includes exploiting unique targets for T cells that are exclusively and robustly expressed by multiple solid cancers and developing technologies that enhance the durability of the T cells. The company has ongoing R & D programs to develop safe and effective adoptive T cell therapies for patients with triple negative breast cancer as well as cancers of the bladder, ovarium, colorectum, prostate, skin, esophagus, lung, or brain. Rachel Abbott has been the CEO of the company since 2023. | Health Technology |
- Stock Market
- Insiders
- Rachel Abbott
